What is the evidence that personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient's disease are aligned with specific therapy, will improve outcomes?

What is the evidence that personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient's disease are aligned with specific therapy, will improve outcomes?

What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient’s disease are aligned with specific therapy, will improve patient outcomes? To what extent are they improved with targeted therapy, in breast, lung (NSLC), and colorectal cancer?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Professor Lynn Wang, MD, PhD, FCAP

Professor Lynn Wang, MD, PhD, FCAP

Professor, Division of Genomic and Molecular Pathology
Founding Medical Director
Genomic and Molecular Pathology
University of Chicago Medical Center
Chicago, IL, USA